Phase 3 N=43 A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD
Attention Deficit Hyperactivity Disorder
Primary: SKAMP — 11.8; 18.9 SKAMP Combined Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,572 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Heart Failure With Preserved Ejection Fraction
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001
Phase 3 N=19 Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
Prostate Adenocarcinoma
Primary: Uptake Value of C11-choline — 6.2 Ratio
Phase 3 N=30 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Number of Participants With Clinical Improvement of Target Lesions — 18 Participants
Phase 3 N=59 Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
Healthy
Primary: Standard Deviation of Lateral Position (SDLP) — 33.2; 34.2; 35.4; 47.4 centimeter (cm) — p=<0.001
Phase 3 N=134 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
X-linked Hypophosphatemia
Primary: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above the LLN (2.5 mg/dL [0.81 mmol/L]) at the Mid-Point of the Dose Interval, as Averaged Across Dose…
Phase 3 N=20 Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)
Liver Disease
Primary: Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1) — 0.104; 0.092; 0.099 min-1
Phase 3 N=100 A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
Coronary Artery Disease
Primary: Target Lesion Failure Rate at 12-months — 4 percentage of participants
Phase 3 N=602 Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Opioid Dependence · Acute Opioid Withdrawal Syndrome
Primary: Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores — 7.8; 7.6; 9.4; 10.2 score on a scale — p=0.0166
Phase 3 N=41 Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment
Depression
Primary: Percentage Change in Depressive Symptoms as Assessed by Hamilton Rating Scale for Depression — 60.83; 61.81 percentage of change in score
Phase 3 N=727 A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
Rhinitis, Allergic, Seasonal
Primary: PRIMARY: Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Equivalence: Per-Protocol Population) — 2.036; 1.904 score on scale
Phase 3 N=680 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period — 74.8 Percentage of Participants
Phase 3 N=506 An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
Overactive Bladder
Primary: Number of Participants With the Indicated Type of Treatment-emergent Adverse Event — 171; 126; 59; 46 participants
Phase 3 N=560 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Brain Cancer
Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037
Phase 3 N=28 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate